Web site provides dentists, patients easy access to relevant topics

May 1, 2007
The site, www.ARESTIN.com, has the latest in periodontal disease information and resources.

WARMINSTER, Pennsylvania--OraPharma, Inc., has recently launched the third generation of its popular Web site, www.ARESTIN.com.

The Web site, originally launched in 2002, quickly became a primary online destination for dentists, hygienists, and patients seeking 24/7 access to the latest information on the treatment of periodontal disease.

The new ARESTIN.com site provides patients and practitioners with easy access to relevant topics, such as:

* Periodontal disease risk factors

* Current clinical research involving ARESTIN plus SRP compared to SRP alone

* Tools and resources to help understand and communicate the need for
consistent diagnosis and comprehensive treatment of periodontal disease, including ARESTIN plus SRP

According to John Lenart, product director for OraPharma Inc.'s ARESTIN, "The redesigned ARESTIN.com has a much cleaner layout and easier navigation, including a robust array of educational, clinical, financial, and reimbursement tools that many dental professionals have told us are 'must-haves' to be a best-in-class oral health Web site.

"This includes recent clinical studies, news items regarding periodontal disease, interactive educational programming, and an updated news feed highlighting periodontal disease in the lay press. The goal of the site is to enable dental professionals to quickly, conveniently, and easily learn how to successfully implement a periodontal treatment program in their offices. As well, patients are educated about the risks and symptoms of periodontal disease, along with the importance of treatment with ARESTIN plus SRP."

ARESTIN.com was created in conjunction with dental health professionals and patients. This was accomplished by working closely with many online dental communities, as well as a three-month long survey for dental professionals and patients that helped OraPharma determine what each group truly wanted to know and how they would like periodontal disease and ARESTIN information presented.

"Without asking our customers and their patients about how to best serve them in the online arena," stated Lenart. "We would have not been true to our mission of exceeding customers' and patients' expectations of providing superior solutions and products designed to increase the quality of patient care and practice productivity. This customer feedback drove our quest for this site to go from 'good enough' to 'great.'"

The site is designed to be equally informative and useful for dental professionals and consumers, with two separate entry and navigation tracks.

OraPharma is a specialty pharmaceutical company specializing in the discovery, development, and commercialization of therapeutics for the treatment of periodontal disease, including ARESTIN (minocycline hydrochloride) Microspheres, 1 mg.

For more information about OraPharma and its products, visit OraPharma.